Skip to main content

Table 2 Association of expression of PD-L1 to clinicopathological characteristics in 261 patients of lung adenocarcinoma

From: Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression

 PD-L1 TPS (%)p value
< 1%1–49%> = 50%
SexMale (n = 131)75 (57.3)24 (18.3)32 (24.4)0.92
Female(n = 130)72 (55.4)27 (20.8)31 (23.8) 
Clinical stageI-II (n = 117)74 (50.3)23 (45.1)20 (31.7)0.04
III + IV (n = 144)73 (49.7)28 (54.9)43 (68.3) 
LAC predominant componentsAcinar57 (38.8)15 (29.4)18 (28.6)< 0.01
Lepidic10 (6.8)3 (5.9)1 (1.6) 
Microp11 (7.5)4 (7.8)7 (11.1) 
Mucinous10 (6.8)0 (0)0 (0) 
Papillary39 (26.5)16 (31.4)11 (17.5) 
Solid20 (13.6)13 (25.5)26 (41.3) 
LACsWith uniform component (n = 114)71 (48.3)21 (41.2)22 (34.9)0.04*
With two components (n = 104)53 (36.1)17 (33.3)34 (54) 
With > two components (n = 43)23 (15.6)13 (25.5)7 (11.1) 
EGFR statusMutated (n = 154)84 (57.1)30 (58.8)40 (63.5)0.7
Wild-typed (n = 107)63 (42.9)21 (41.2)23 (36.5) 
  1. Abbreviations: LAC lung adenocarcinoma, Microp Miropapillary; *P, with some component compared with those without corresponding component